HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough’s “Faster” Claims For Lotrimin Ultra Not Accurate – NAD

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough Healthcare Products should modify claims that its Lotrimin Ultra relieves athlete's foot in less time than Novartis Consumer Healthcare's Lamisil Defense, the National Advertising Division recommends

You may also be interested in...



Lamisil Gel Ads Should Emphasize “Between The Toes” Cure Only – NAD

Novartis Consumer Health should modify claims for its Lamisil AT Gel Advanced athlete's foot treatment to emphasize the product has been proven effective in between the toes only, the National Advertising Division states in a decision announced March 3

Lotrimin Ultra Antifungal Switch Approved By FDA

Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name

Novartis Lamisil AT OTC Antifungal Said To Work In One Week

Novartis said its new OTC athlete's foot medication Lamisil AT Cream is the only nonprescription medication that cures athlete's foot with one week of treatment in its announcement that FDA has approved the Rx-to-OTC switch.

Topics

UsernamePublicRestriction

Register

RS138467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel